N-substituted anilines, inhibitors of phospholipases A.sub.2
US5324747A · kind A · utility
14Cited by
7References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 1992 |
| Grant date | Jun 28, 1994 |
| Priority date | — |
| Expiry date | Jul 15, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/74
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, n, m, o, p and q are as hereinafter set forth, and, when R.sub.2 is hydrogen, pharmaceutically acceptable salts thereof with bases, are described. The compounds of formula 1 are potent inhibitors of phospholipases A.sub.2 (PLA.sub.2 's) and are therefore useful in the treatment of inflammatory diseases, such as psosiasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma induced inflammation, such as spinal cord injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.